Keratoprosthesis in autoimmune disease

Ocul Immunol Inflamm. 2010 Aug;18(4):275-80. doi: 10.3109/09273941003682300.

Abstract

Purpose: To describe the clinical features and course of 2 patients with autoimmune diseases and their experience with the Boston keratoprosthesis. To draw on general medical literature to try to better understand recurrent complications.

Methods: Retrospective review of 2 patients treated with Boston keratoprostheses. The clinical histories, examinations, and other diagnostics were reviewed. A literature review was performed.

Results: The first patient presented with end-stage ocular disease secondary to toxic epidermal necrolysis (TENS). The second patient presented with end-stage ocular disease secondary to mucous membrane pemphigoid (MMP). Both patients underwent treatment with the Boston keratoprosthesis. Both patients suffered numerous corneal melts requiring multiple repeat implantations.

Conclusions: Patients with corneal blindness secondary to autoimmune disease often fare poorly with available surgical treatments. Study of existing literature on prosthetic device complications in autoimmune diseases may help uncover common mechanisms of tissue destruction to establish perioperative immunomodulatory regimens targeted to specific underlying diseases.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Alternaria / drug effects
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Autoimmune Diseases / complications*
  • Blindness / etiology
  • Blindness / surgery*
  • Corneal Diseases / etiology
  • Corneal Diseases / surgery*
  • Female
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Mycoses / drug therapy
  • Pemphigoid, Benign Mucous Membrane / complications*
  • Prednisolone / therapeutic use
  • Prostheses and Implants*
  • Prosthesis Implantation*
  • Stevens-Johnson Syndrome / complications*
  • Treatment Outcome
  • Visual Acuity / drug effects

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Prednisolone
  • Infliximab
  • Mycophenolic Acid